Most Popular
-
1
Dongduk Women’s University halts coeducation talks
-
2
Defense ministry denies special treatment for BTS’ V amid phone use allegations
-
3
Russia sent 'anti-air' missiles to Pyongyang, Yoon's aide says
-
4
OpenAI in talks with Samsung to power AI features, report says
-
5
Two jailed for forcing disabled teens into prostitution
-
6
Trump picks ex-N. Korea policy official as his principal deputy national security adviser
-
7
South Korean military plans to launch new division for future warfare
-
8
Gold bars and cash bundles; authorities confiscate millions from tax dodgers
-
9
Kia EV9 GT marks world debut at LA Motor Show
-
10
Teen smoking, drinking decline, while mental health, dietary habits worsen
Boryung Pharma to release hypertension medication in S. America
By 정민경Published : Sept. 26, 2016 - 13:54
[THE INVESTOR] South Korea’s Boryung Pharmaceutical has signed a contract with Mexican firm Stendhal International to supply medicine for treating hypertension in South America, the firm said on Sept. 26.
The agreement is worth 30 billion won (US$27.1 million) -- which is 7.48 percent of the firm’s revenue in 2015. Boryung plans to gradually release more products in South America by 2024 via its partnership with Stendhal.
The Korean firm has been seeking to expand into more markets for its oral hypertension medication such as Dukarb and Tuvero.
The two are the firm’s mainstay products and belong to a class of medications called angiotensin II receptor antagonists, which is known to help lower blood pressure by fighting a chemical that causes blood vessels to tighten.
Prior to the agreement, Boryung had released its selection of other high blood pressure treatments such as Kanarb and Kanarb Plus in South America in 2011 and 2013, respectively.
By Jung Min-kyung (mkj1105@heraldcorp.com)
The agreement is worth 30 billion won (US$27.1 million) -- which is 7.48 percent of the firm’s revenue in 2015. Boryung plans to gradually release more products in South America by 2024 via its partnership with Stendhal.
The Korean firm has been seeking to expand into more markets for its oral hypertension medication such as Dukarb and Tuvero.
The two are the firm’s mainstay products and belong to a class of medications called angiotensin II receptor antagonists, which is known to help lower blood pressure by fighting a chemical that causes blood vessels to tighten.
Prior to the agreement, Boryung had released its selection of other high blood pressure treatments such as Kanarb and Kanarb Plus in South America in 2011 and 2013, respectively.
By Jung Min-kyung (mkj1105@heraldcorp.com)
